Australia markets close in 56 minutes

Acurx Pharmaceuticals, Inc. (ACXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.0200-0.0100 (-0.49%)
At close: 04:00PM EDT
2.0000 -0.02 (-0.99%)
After hours: 05:54PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 31.83M
Enterprise value 24.36M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.55
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.67

Trading information

Stock price history

Beta (5Y monthly) -1.90
52-week change 3-32.44%
S&P500 52-week change 321.08%
52-week high 38.8200
52-week low 31.1700
50-day moving average 32.4404
200-day moving average 32.8939

Share statistics

Avg vol (3-month) 3100.58k
Avg vol (10-day) 3105.3k
Shares outstanding 515.76M
Implied shares outstanding 615.84M
Float 813.35M
% held by insiders 115.26%
% held by institutions 111.80%
Shares short (15 Apr 2024) 4579.12k
Short ratio (15 Apr 2024) 45.6
Short % of float (15 Apr 2024) 44.34%
Short % of shares outstanding (15 Apr 2024) 43.68%
Shares short (prior month 15 Mar 2024) 4294.47k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-106.65%
Return on equity (ttm)-243.33%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-14.58M
Diluted EPS (ttm)-1.1500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)7.47M
Total cash per share (mrq)0.47
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)2.53
Book value per share (mrq)0.32

Cash flow statement

Operating cash flow (ttm)-9.8M
Levered free cash flow (ttm)-4.33M